Clinical trials: Clopidogrel, completed
Coronary Artery Disease, Diabetes Mellitus
Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk
Ramadan fasting (RF) has been shown to be associated with vascular and metabolic disorders including glycemic control and lipid profile. It may also alter pharmacologic properties of some medications.
- Trial name
- RFeCloR (NCT02624583)
- Where
- 2 sites in Tunisia
- Volunteers
- 98 people
- Sponsor
- University of Monastir
Platelet Reactivity
Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01463150
- Testing
- Clopidogrel, Prasugrel
- Where
- Greece
- Volunteers
- 27 people
- Sponsor
- University of Patras
Healthy
Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine
Clopidogrel is a platelet aggregation inhibitor witch prevents thrombotic events in patients with atherosclerotic vascular disease. To date, 4 to 30 % of patients are considered as poor, low or non-responder to this therapeutic.
- Trial name
- PLATINE (NCT00732290)
- Testing
- Clopidogrel then fluoxetine+clopidogrel, Fluoxetine+clopidogrel then clopidogrel
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Osteoarthritis of the Knee, Coagulopathy
Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants
The purpose of this study is to see if using a topical nonsteroidal antiinflammatory drug (Pennsaid) to treat osteoarthritis knee pain will affect coagulation values in patients who are also taking anticoagulant or antithrombotic…
- Trial name
- ATCCTCP-1 (NCT01511939)
- Testing
- Pennsaid
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Nathan Wei, MD, FACP, FACR:
Healthy Volunteers
An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel
The primary purpose of this study is to assess whether esomeprazole 20 mg/Acetyl Salicylic Acid (ASA) 81 mg affect the metabolism of clopidogrel.
- Trial name
- NCT01210339
- Testing
- Clopidogrel, Esomeprazole/ASA
- Where
- Sweden
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with pantoprazole 80 mg/day compared to…
- Trial name
- NCT01129427
- Testing
- Clopidogrel, Pantoprazole
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Myocardial Infarction
Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction
COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible…
- Trial name
- NCT00222573
- Testing
- clopidogrel and metoprolol
- Where
- 2 sites in China, United Kingdom
- Volunteers
- 46,000 people
- Sponsor
- University of Oxford
Stroke
Standard Medical Management in Secondary Prevention of Ischemic Stroke in China
The purposes of the study are to analyse the cross-section data of secondary stroke prevention in China and to carry out a standard medical management including medicine and interactive education program,and to evaluate the…
- Trial name
- SMART (NCT00664846)
- Testing
- Aspirin / Clopidogrel, Atorvastatin / Simvastatin, Asprin / Clopidogrel, Atorvastatin / Simvastatin
- Where
- 46 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking Union Medical College Hospital
ST Elevation Myocardial Infarction, Fibrinolysis
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
This is a two-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers (Patras University Hospital and Konstantopoulio…
- Conditions
- ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor
- Trial name
- NCT01950416
- Testing
- Ticagrelor 180mg loading dose and 90mg bid maintenance dose, Clopidogrel 600mg loading dose and 150mg maintenance dose
- Where
- 2 sites in Greece
- Volunteers
- 56 people
- Sponsor
- University of Patras
Coronary Artery Disease, Percutaneous Coronary Intervention
Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism
The purpose of this study is to determine the impact of adjunctive cilostazol versus high maintenance-dose clopidogrel on platelet inhibition in carriers and non-carriers of the loss-of-function CYP2C19 mutant allele.
- Trial name
- ACCEL-2C19 (NCT01012193)
- Testing
- cilostazol 100mg bid or clopidogrel 150-mg daily
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Gyeongsang National University Hospital
Coronary Heart Disease, Angina Pectoris
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d.
- Conditions
- Coronary Heart Disease, Angina Pectoris, Atherosclerosis
- Trial name
- ASCET (NCT00222261)
- Testing
- aspirin, clopidogrel
- Where
- Norway
- Volunteers
- 1,001 people
- Sponsor
- Ullevaal University Hospital
Platelet Reactivity
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
- Trial name
- NCT03679091
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Artery Disease
Prasugrel With Lower Dose - Loading Dose
Although prasugrel, recently available thienopyridine derivative, exhibits rapid and potent platelet inhibition, concerns of low on-treatment platelet reactivity have been suggested especially in East Asian ethnicities.
- Trial name
- PRELOAD-LD (NCT02070159)
- Testing
- Clopidogrel 600 mg, Prasugrel 30 mg, Prasugrel 60 mg
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Dong-A University
Adverse Drug Reaction
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program
The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested.
- Trial name
- INGenious (NCT02297126)
- Testing
- Pharmacogenetic Intervention Arm (pharmacogenetic testing)
- Where
- United States
- Volunteers
- 4,465 people
- Sponsor
- Indiana University
Healthy
Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects
The primary objective of the study (Main Part 2) was to investigate whether and to which extent a combination of multiple oral doses (steady state conditions) of 75 mg of clopidogrel q.d.
- Trial name
- NCT02171598
- Testing
- Clopidogrel, Dabigatran high dose, Dabigatran low dose
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
This is a multicenter, randomized, double-blind, cross-over study to compare the pharmacodynamic response in subjects with Acute Coronary Syndrome receiving a 10-mg maintenance dose (MD) of prasugrel compared with a 150-mg…
- Trial name
- NCT00385944
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Atrial Fibrillation, Vascular Risk
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)
The purpose of this study is to determine if the combination of clopidogrel 75mg once daily (od) plus aspirin 100mg daily (recommended dose) is better than aspirin alone (100mg daily recommended dose) for preventing vascular…
- Trial name
- NCT00249873
- Testing
- clopidogrel (SR25990C)
- Where
- 30 sites in United States, Argentina and 28 more
- Volunteers
- 7,554 people
- Sponsor
- Sanofi
ST-segment Elevation Myocardial Infarction
EROSION III: OCT- vs Angio-based Reperfusion Strategy for STEMI
Brief Summary: This study is a prospective, multicenter, randomized, controlled trial aimed to compare the reperfusion strategy and clinical outcomes of STEMI patients treated by angiography-guided vs. OCT-guided PCI.
- Trial name
- NCT03571269
- Testing
- Optical coherence tomography-guided reperfusion strategy
- Where
- 12 sites in China
- Volunteers
- 246 people
- Sponsor
- Harbin Medical University
Cardiovascular Diseases
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
The purpose of this randomized, cross-over study, is to ascertain if ticagrelor, but not prasugrel or clopidogrel, is associated to an improved endothelial function as assessed with peripheral arterial tonometry and markers of…
- Trial name
- HI-TECH (NCT02587260)
- Testing
- Ticagrelor, Prasugrel, Clopidogrel
- Where
- 5 sites in Italy, Netherlands and 2 more
- Volunteers
- 54 people
- Sponsor
- Erasmus Medical Center
Coronary Artery Disease
Clopidogrel/Aspirin Interaction Study
This study will explore the effect of different doses of aspirin on the effects of double-dose or standard dose clopidogrel.
- Trial name
- INTERACTION (NCT01102439)
- Testing
- Clopidogrel, Aspirin
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Population Health Research Institute